Cybin announces publication of EMBARK, a model of psychedelic-assisted psychotherapy that integrates leading clinical approaches to promote effective facilitation and supportive healing.

Novamind Inc reports its Q3 for fiscal 2022. Quarterly revenues of CAD$3,227,352 represent a q-o-q of 32%. Novamind also expanded into the Arizona market in Q2 with its clinic operations.

Optimi Health announces a new supply agreement with Filament Health to supply Filament with psilocybin mushrooms.

Cybin Inc announces the submission of an Investigational New Drug application (IND) to the FDA for a Phase 1/2a clinical trial of CYB003 for major depressive disorder (MDD).

Small Pharma issues a corporate update, reporting R&D and IP progress, with ~CAD$40 million in cash as of February 28, 2022.

Awakn Life Sciences announces filing a patent application for the treatment of behavioral addictions with ketamine-assisted psychotherapy.

Pharmather announces a new development agreement with CCBIO to create a proprietary wearable ketamine delivery solution for mental health.

Compass Pathways announces the release of the largest randomized, controlled, double-blind study ever completed on psilocybin-assisted therapy.

MindMed announces the appointment of Schond L. Greenway as its new CFO, bringing a wealth of experience in banking and corporate finance.